Aclasta

Reclast - known as Aclasta outside the United States - was already on the U.S. and European markets as a one-a-year therapy.

Canadian Online Health News 2009

Gains European Union Approval Novartis AG said Friday that the European Union approved its bone drug Aclasta, a treatment that needs to be taken only once a year.

Novartis Says Bone Drug Aclasta 2007

Switzerland-based Novartis said the EU regulator approved Aclasta for the treatment of women with postmenopausal osteoporosis.

Novartis Says Bone Drug Aclasta 2007

Aclasta has been shown to reduce the risk of fractures in areas of the body typically affected by osteoporosis, including the spine, wrists and hips.

Novartis Says Bone Drug Aclasta 2007

Aclasta is given as a 15-minute infusion once a year, while established drugs of this type are taken orally, typically once a week or once a month.

Novartis Says Bone Drug Aclasta 2007

These recently launched products - Exelon Patch, Exjade, Reclast/Aclasta Gilenya - now comprise 29% of division sales, compared to 22% in the same period last year.

Reuters: Press Release 2011

Jimenez, however, said recently launched products such as eye medicine Lucentis and osteoporosis drug Aclasta, where sales jumped 59% and 45%, respectively, should develop into key growth drivers in the future.

FOXNews.com Goran Mijuk 2010

Lucentis (ranibizumab) for the treatment of age-related macular degeneration shot up 64% to $374 million, while Reclast/Aclasta (zoledronic acid) for osteoporosis climbed 73% to $147 million.

PharmaTimes World News 2010

Lucentis (ranibizumab) for the treatment of age-related macular degeneration shot up 64% to $374 million, while Reclast/Aclasta (zoledronic acid) for osteoporosis climbed 73% to $147 million.

PharmaTimes World News 2010

Jimenez, however, said recently launched products such as eye medicine Lucentis and osteoporosis drug Aclasta, where sales jumped 59% and 45%, respectively, should develop into key growth drivers in the future.

FOXNews.com Goran Mijuk 2010